Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M161Revenue $M30.0Net Margin (%)-68.3Altman Z-Score-7.7
Enterprise Value $M167EPS $-1.1Operating Margin %-59.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-68.2Higher ROA y-yY
Price/Book10.910-y EBITDA Growth Rate %--Quick Ratio1.5Cash flow > EarningsY
Price/Sales6.05-y EBITDA Growth Rate %--Current Ratio1.8Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %-360.0ROA % (ttm)-39.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-84.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M17.2ROIC % (ttm)-93.3Gross Margin Increase y-yN

Gurus Latest Trades with CRME

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CRMEJulian Robertson 2012-12-31 Sold Out -0.11%$1.25 - $2.5
($1.57)
$ 9.33494%Sold Out0
CRMEJulian Robertson 2011-12-31 Reduce-0.48%$9.35 - $17.85
($13.14)
$ 9.33-29%Reduce 18.26%319,221
CRMEGeorge Soros 2011-12-31 Sold Out -0.0008%$9.35 - $17.85
($13.14)
$ 9.33-29%Sold Out0
CRMEJulian Robertson 2011-09-30 Reduce-0.69%$16.45 - $27.95
($19.93)
$ 9.33-53%Reduce 22.89%390,518
CRMEGeorge Soros 2011-09-30 Add$16.45 - $27.95
($19.93)
$ 9.33-53%Add 4.55%2,760
CRMEGeorge Soros 2011-06-30 Buy $19.25 - $28.85
($23.59)
$ 9.33-60%New holding2,640
CRMEJulian Robertson 2011-03-31 Add0.16%$21.3 - $34.95
($29.29)
$ 9.33-68%Add 6.15%506,468
CRMEJulian Robertson 2010-12-31 Add0.34%$23 - $32.75
($27.99)
$ 9.33-67%Add 9.55%477,123
CRMEGeorge Soros 2010-12-31 Sold Out $23 - $32.75
($27.99)
$ 9.33-67%Sold Out0
CRMEJulian Robertson 2010-09-30 Add0.4%$29.85 - $46.55
($36.3)
$ 9.33-74%Add 10.01%435,523
CRMEGeorge Soros 2010-09-30 Reduce$29.85 - $46.55
($36.3)
$ 9.33-74%Reduce 3.67%2,100
CRMEJulian Robertson 2010-06-30 Buy 3.53%$33.05 - $43.4
($40.09)
$ 9.33-77%New holding395,881
CRMEGeorge Soros 2010-06-30 Buy $33.05 - $43.4
($40.09)
$ 9.33-77%New holding2,180
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CRME is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CRME: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Archibald, JenniferSenior Officer 2014-09-08Buy75$7.2927.98 view
Archibald, JenniferSenior Officer 2014-09-05Buy4,100$7.2528.69 view
Archibald, JenniferSenior Officer 2014-09-05Buy100$7.2229.22 view
Archibald, JenniferSenior Officer 2014-09-05Buy3,259$6.739.25 view
Hunter, William L.Director, Senior Officer 2014-09-05Buy31,000$6.7438.43 view
Hunter, William L.Director, Senior Officer 2014-09-04Buy19,000$6.6540.3 view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-27Sell2,000$8.657.86 view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-26Sell1,500$8.657.86 view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell300$8.638.11 view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell2,000$8.647.99 view

Press Releases about CRME :

    Quarterly/Annual Reports about CRME:

      News about CRME:

      Articles On GuruFocus.com
      Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
      Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
      Julian Robertson Keeps Buying CRME, Selling AAPL Apr 13 2011 
      More Word of Wisdom from Julian Robertson; Top 2Q10 Purchases: GOOG, EBAY, AAPL, CRME, GS Nov 04 2010 

      More From Other Websites
      Should You Get Rid of Calithera Biosciences (CALA) Now? - Tale of the Tape May 18 2015
      Cardiome Reports First Quarter 2015 Financial Results May 13 2015
      Cardiome reports 1Q loss May 13 2015
      Cardiome reports 1Q loss May 13 2015
      Cardiome Reports First Quarter 2015 Financial Results May 13 2015
      Cardiome Reports First Quarter 2015 Financial Results May 13 2015
      Cardiome and AOP Orphan Pharma Enter ESMOCARD Commercialization Agreement May 12 2015
      Cardiome and AOP Orphan Pharma Enter ESMOCARD Commercialization Agreement May 12 2015
      Cardiome and AOP Orphan Pharma Enter ESMOCARD Commercialization Agreement May 12 2015
      Cardiome to Hold First Quarter 2015 Financial Results Conference Call on May 13 May 07 2015
      Cardiome To Hold First Quarter 2015 Financial Results Conference Call On May 13 May 07 2015
      Cardiome To Hold First Quarter 2015 Financial Results Conference Call On May 13 May 07 2015
      Zacks Rank #5 Additions for Wednesday - Tale of the Tape Apr 29 2015
      Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference Apr 27 2015
      Cardiome to Present at Bloom Burton & Co. Healthcare Investor Conference Apr 27 2015
      Cardiome to Present at Bloom Burton & Co. Healthcare Investor Conference Apr 27 2015
      Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities Apr 09 2015
      Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities Apr 09 2015
      Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities Apr 09 2015
      CARDIOME PHARMA CORP Financials Apr 02 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK